Journal
TUBERCULOSIS
Volume 91, Issue 1, Pages 65-66Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.tube.2010.10.001
Keywords
Pulmonary; Inhalation; Respirable; Drug resistance; Granuloma
Categories
Funding
- CSIR NMITLI [5/258/6]
- Indian Council of Medical Research
- CSIR
Ask authors/readers for more resources
Factors that are inimical to the success of inhaled therapies for tuberculosis (TB) include: (i) lack of access of inhaled therapies to poorly-aerated areas of the tubercular lung; (ii) limited ability to penetrate biofilms formed by extracellular bacilli; (iii) selection for resistant bacilli on account of administration of low doses of anti-TB agents; (iv) induction of inflammation and/or immunopathology in the airways and lungs; and (v) anomalies in antigen processing and presentation of vaccines delivered to the lungs. Further, the claim that inhaled therapies rescue alternatively-activated macrophages may not be applicable to all individuals. Fortunately, there are ways and means to address each of the above factors. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available